Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05054010

Identification of Breast Cancer Specific Markers in Patients Compared to Healthy Participants

Identification and Characterization of Commercial RUO Antibodies for the Detection of Specific Breast Cancer Tumoral Markers Expressed in Potential Circulating Tumoral Cells (CTCs)

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
84 (actual)
Sponsor
Tethis S.p.A. · Industry
Sex
Female
Age
18 Years
Healthy volunteers
Accepted

Summary

This is an exploratory research study with the aim of identifying specific cancer biomarkers in various subtypes of breast cancer. Blood samples will be collected from 60 participants divided into 40 patients and 20 healthy donors. An amendment to the research has been proposed to enroll 24 additional participants divided into 12 patients and 12 healthy donors.

Detailed description

In this research study different commercial RUO (Research Use Only) antibodies will be purchased and then tested on blood samples obtained by participants affected by breast cancer and by healthy participants as control. Sixty participants will be enrolled belonging to different categories: 20 participants affected by early breast cancer, 20 participants affected by metastatic breast cancer, and 20 healthy volunteers to be used as negative control. After signing the informed consent form, participants will be screened to evaluate if they meet the eligibility criteria. If all the criteria are met, participants will be enrolled into the study and will be asked to provide some demographic and other data. A 13 ml blood sample will be collected by the subjects and shipped to Tethis laboratories in order to be processed and analysed. An amendment has been proposed to enroll 24 additional participants divided into 12 patients and 12 healthy donors. During the amendment, participants will be enrolled to test the analytical capacity of the antibodies evaluated in the first part on samples processed with different methods in order to select the optimal one for future development.

Conditions

Timeline

Start date
2021-10-04
Primary completion
2026-12-01
Completion
2026-12-01
First posted
2021-09-23
Last updated
2026-02-02

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05054010. Inclusion in this directory is not an endorsement.